财务状况 - 公司2022年第三季度营收为1.14亿美元，同比增长18%。[1] - 公司2022年前三季度营收为3.24亿美元，同比增长17%。[1] - 公司2022年第三季度毛利率为78.5%，同比下降1.5个百分点。[1] - 公司2022年前三季度毛利率为79.1%，同比下降1.1个百分点。[1] 现金流 - 公司2022年第三季度经营活动产生的现金流量净额为2,800万美元。[1] - 公司2022年前三季度经营活动产生的现金流量净额为7,800万美元。[1] - 公司2022年第三季度自由现金流为2,300万美元。[1] - 公司2022年前三季度自由现金流为6,800万美元。[1] 用户增长 - 公司2022年第三季度月活跃用户数达到1.06亿，同比增长13%。[1] - 公司2022年第三季度付费用户数达到2,200万，同比增长16%。[1] - 公司2022年第三季度付费转化率为20.8%，同比提升0.5个百分点。[1] 产品发展 - 公司在2022年第三季度推出了新的视频编辑功能。[1] - 公司在2022年第三季度推出了新的社交功能。[1] - 公司在2022年第三季度推出了新的电商功能。[1] 未来展望 - 公司预计2022年全年营收将达到4.4亿至4.5亿美元。[1] - 公司预计2022年全年经营利润率将在25%至27%之间。[1] - 公司将继续专注于产品创新和用户增长。[1]

Cencora (COR) is slated to report fiscal fourth-quarter 2024 results on Nov. 06, before market open.In the last reported quarter, the company delivered a positive earnings surprise of 5.03%. COR’s earnings beat estimates in all the trailing four quarters, delivering an average surprise of 6.59%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $77.68 billion, up 12.7% compared with the prior-year quarter. The consensus ...

Analysts on Wall Street project that Cencora (COR) will announce quarterly earnings of $3.21 per share in its forthcoming report, representing an increase of 12.2% year over year. Revenues are projected to reach $77.68 billion, increasing 12.7% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this time ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Cencora (COR) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better than exp ...

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 14.7% compared with 2.8% growth of the industry. The S&P 500 Composite has risen 22.5% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing dr ...

Cencora (COR) shares soared 3.7% in the last trading session to close at $233.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.8% loss over the past four weeks. Cencora recorded a strong price rise driven by investors' optimism surrounding the company's upcoming earnings release, scheduled on Nov. 6, 2024. The Zacks Consensus Estimate for the fiscal fourth quarter suggests a revenue growth of 12.7% and earnings growth of 12. ...

文章核心观点 - 该公司是一家处方药分销商,在过去两个季度的财报中都超出了预期 [1][2][3] - 公司最近的盈利预测也有所上调,加上良好的股票评级,预示着公司下一个季度的财报可能会再次超出预期 [2][3] - 虽然负面的盈利预测差异并不意味着公司业绩会不佳,但投资者仍应关注这一指标来评估公司的表现 [4] 行业概况 - 公司所属的医疗服务行业 [1] 公司财务表现 - 公司最近两个季度的财报均超出了预期,平均超出幅度为4.57% [1][2][3] - 上一个季度,公司的每股收益预期为$3.65,实际为$3.80,超出4.11% [1][3] - 本季度,公司的每股收益预期为$3.18,实际为$3.34,超出5.03% [1][3]

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 10.3% year to date compared with the industry's 7.4% growth. The S&P 500 Index has risen 17.7% in the same time frame. Cencora is one of the world's largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve ...

文章核心观点 - 公司第三季度财报超预期,全年业绩指引上调 [2][8] - 美国医疗解决方案业务收入增长12.2%,带动整体收入增长 [3] - 国际医疗解决方案业务收入持平,但在汇率影响下实现5.8%的增长 [3][4] - 公司毛利率和营业利润率同比有所下降 [5] - 公司现金流和现金储备均有所增加 [6] - 公司宣布派发季度股息 [7] 根据目录分类总结 财务业绩 - 第三季度调整后每股收益为3.34美元,同比增长14.4% [2] - 第三季度营收为742亿美元,同比增长10.9% [3] - 毛利润为24亿美元,同比增长6.5%;毛利率为3.25%,同比下降13个基点 [5] - 营业利润为6.725亿美元,持平;营业利润率为0.91%,同比下降9个基点 [5] - 经营活动产生的现金流出为24.8亿美元,同比增加 [6] - 现金及现金等价物余额为33.1亿美元,较上季度增加 [6] 业务表现 - 美国医疗解决方案业务收入增长12.2%,主要受益于GLP-1药物需求旺盛 [3] - 国际医疗解决方案业务收入持平,但在汇率影响下实现5.8%的增长 [3][4] - 国际业务营业利润下降4.1%,主要受欧洲分销业务IT费用上升和全球专业物流业务利润下降影响 [4] 展望和指引 - 公司上调了2024财年的收益和收入指引 [8] - 调整后每股收益预计13.55-13.65美元,同比增长13-13.8% [8] - 收入预计增长12%,高于此前10-12%的指引 [8] - 美国医疗解决方案业务收入预计增长12-13% [8] - 国际医疗解决方案业务收入预计增长4-6% [8] - 调整后营业利润预计增长10-11% [8]

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 16.6% compared with 6% growth of the industry. The S&P 500 Composite has risen 17.5% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing drug ...